Dow Jones
37.942,76 -443,33 (-1,15%) Nasdaq
15.781,00 -202,08 (-1,26%) Nikkei 225
38.405,66 +470,90 (+1,24%) EUR/USD
1,0679 -0,0046 (-0,43%) Bitcoin EUR
56.152,90 -2.515,96 (-4,29%) CMC Crypto 200
1.288,13 -50,93 (-3,81%)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Chiusura precedente | 35,64 |
| Aperto | 35,14 |
| Denaro | 36,14 x 100 |
| Lettera | 36,79 x 100 |
| Min-Max giorno | 34,93 - 36,79 |
| Intervallo di 52 settimane | 3,03 - 49,87 |
| Volume | |
| Media Volume | 372.240 |
| Capitalizzazione | 380,728M |
| Beta (5 anni mensile) | 2,47 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -10,31 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 55,00 |
GlobeNewswireCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
